Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Murky sales report imo

<< Previous

Bullboard Posts

Next >>

Comment by Qwerty54321on Jul 10, 2024 10:09pm

73 Views

Post# 36127597

RE:Murky sales report imo

That's how I read it. Drawn to exactly the same sentence.

palinc2000 wrote:
Why dont they break down the sales report with the end demand from partients and variations (plus or minus) in inventories in the sales channels
Gloating over 49% increase in Egrifta sales where most of the increase it seems is purely inventory replesnisment .....Why keep everybody guessing by not providing exact metrics
They have covered their behind by adding"
moving forward we expect sales to align with patient demand now that inventory levels have returned to normal"
Not man enough to be fully transparent .....
I am open to hearing arguments proving that I am reading this wrong